-
公开(公告)号:US06641818B1
公开(公告)日:2003-11-04
申请号:US09723368
申请日:2000-11-28
申请人: Patricia G. Spear , Morgyn S. Warner , Robert J. Geraghty , Wanda M. Martinez , Rebecca I. Montgomery , Gary H. Cohen , Roselyn J. Eisenberg , Charles J. Whitbeck , Claude Krummenacher
发明人: Patricia G. Spear , Morgyn S. Warner , Robert J. Geraghty , Wanda M. Martinez , Rebecca I. Montgomery , Gary H. Cohen , Roselyn J. Eisenberg , Charles J. Whitbeck , Claude Krummenacher
IPC分类号: A61K39295
CPC分类号: C07K14/005 , A61K38/00 , A61K39/00 , C12N2710/16622
摘要: A cellular herpesvirus entry protein, or a mutant, a homolog, a derivative, a variant or a biologically active fragment thereof, suspended in a pharmaceutically active carrier in an amount effective to inhibit entry of an alphaherpesvirus into a cell, wherein the cellular herpesvirus entry protein is a member of the immunoglobulin superfamily, is provided and method of use thereof
摘要翻译: 悬浮在药物活性载体中的细胞疱疹病毒入口蛋白或其突变体,同源物,衍生物,变体或生物活性片段,其有效抑制α-疱疹病毒进入细胞的量,其中细胞疱疹病毒入口 蛋白质是免疫球蛋白超家族的成员,提供其使用方法
-
公开(公告)号:US06541459B1
公开(公告)日:2003-04-01
申请号:US09658056
申请日:2000-09-08
申请人: Gary H. Cohen , Roselyn J. Eisenberg , Tao Peng , Gary Dubin
发明人: Gary H. Cohen , Roselyn J. Eisenberg , Tao Peng , Gary Dubin
IPC分类号: A01N4304
CPC分类号: C07K14/005 , A61K38/00 , A61K39/00 , A61K48/00 , C12N2710/16622
摘要: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.
摘要翻译: 本发明涉及包含单纯疱疹病毒糖蛋白H-糖蛋白L复合物的单纯疱疹病毒疫苗。 本发明还涉及包含编码单纯疱疹病毒糖蛋白H-糖蛋白L复合物的DNA的疫苗。 还包括特异性结合单纯疱疹病毒糖蛋白H-糖蛋白L复合物的抗体和编码它的DNA。
-
公开(公告)号:US6156319A
公开(公告)日:2000-12-05
申请号:US904484
申请日:1997-07-31
申请人: Gary H. Cohen , Roselyn J. Eisenberg , Tao Peng , Gary Dubin
发明人: Gary H. Cohen , Roselyn J. Eisenberg , Tao Peng , Gary Dubin
IPC分类号: A61K38/00 , A61K39/00 , A61K48/00 , A61P31/22 , C07K14/035 , C12N15/38 , A61K39/245 , C12M15/38
CPC分类号: C07K14/005 , A61K38/00 , A61K39/00 , A61K48/00 , C12N2710/16622
摘要: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.
-
公开(公告)号:US5654174A
公开(公告)日:1997-08-05
申请号:US499568
申请日:1995-07-07
CPC分类号: C07K14/005 , A61K38/00 , A61K39/00 , C12N2710/14143 , C12N2710/16622 , Y10S930/224
摘要: The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues. When expressed in Sf9 cells, cleavage of the melittin signal peptide results in the presence of aspartate and proline residues at the amino terminus of the variant molecule. The amino acid sequence of gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 2 and the preferred DNA sequence encoding gD-1(.DELTA.290-299t) is set out in SEQ ID NO: 1. Administration of gD variant molecules of the invention to mammalian subjects, especially humans, for the purpose of preventing HSV infection and/or ameliorating pathological sequelae of HSV infection is specifically contemplated.
摘要翻译: 本发明提供能够预防1型和/或2型单纯疱疹病毒感染细胞的变体HSV-1糖蛋白D和HSV-2糖蛋白D分子。还提供了编码变体gD分子的新型纯化和分离的多核苷酸。 HSV gD-1和gD-2区IV变体或其片段是本发明具体考虑的。 目前优选的变体分子gD-1(DELTA 290-299t)是在融合蛋白的Sf9细胞中重组表达的产物,包括蜜蜂蜂毒素和巴顿菌株HSV-1 gD的信号肽,其中(1)Patton菌株氨基酸 成熟gD-1蛋白的残基290至299已被氨基酸残基精氨酸,赖氨酸,异亮氨酸和苯丙氨酸替代,(2)Patton菌株氨基酸残基308至369被五个组氨酸残基取代。 当在Sf9细胞中表达时,蜂毒肽信号肽的切割导致在变体分子的氨基末端存在天冬氨酸和脯氨酸残基。 gD-1(DELTA 290-299t)的氨基酸序列示于SEQ ID NO:2中,编码gD-1(DELTA 290-299t)的优选DNA序列列于SEQ ID NO:1中。 具体考虑本发明的gD变体分子对于哺乳动物受试者,特别是人来说是为了预防HSV感染和/或改善HSV感染的病理后遗症的目的。
-
公开(公告)号:US09089537B2
公开(公告)日:2015-07-28
申请号:US13578976
申请日:2011-02-25
IPC分类号: A61K39/12 , A61K39/245 , C07K14/005 , A61K39/00
CPC分类号: A61K39/245 , A61K39/12 , A61K2039/5252 , A61K2039/53 , A61K2039/55505 , A61K2039/55555 , A61K2039/55572 , A61K2039/70 , C07K14/005 , C12N2710/16622 , C12N2710/16634
摘要: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
摘要翻译: 本公开一般涉及1型和/或2型单纯疱疹病毒(HSV)的疫苗组合物。疫苗包含病毒的分离的抗原或糖蛋白亚基,任选地具有佐剂,例如阳离子脂质体DNA复合物(CLDC)。 本公开还公开了使用这些组合物接种受试者的方法。
-
6.
公开(公告)号:US07560116B2
公开(公告)日:2009-07-14
申请号:US11010979
申请日:2004-12-13
申请人: Gary H. Cohen , Roselyn J. Eisenberg , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
发明人: Gary H. Cohen , Roselyn J. Eisenberg , John Charles Whitbeck , Lydia Aldaz-Carroll , Bernard Moss , Shlomo Lustig , Christiana Fogg
IPC分类号: A61K39/38 , A61K39/12 , A61K39/295 , A61K39/285 , C07K17/00 , A61K39/187
CPC分类号: C07K14/005 , A61K39/12 , A61K39/285 , A61K2039/505 , A61K2039/53 , C07K16/081 , C07K2317/76 , C12N2710/24122 , C12N2710/24134
摘要: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
摘要翻译: 本发明涉及包含可溶性截短痘病毒包膜蛋白的痘病毒疫苗。 本发明还涉及包含编码这种蛋白质的核酸的疫苗。 还包括特异性结合蛋白质的抗体及其编码的核酸,以及使用上述疫苗,抗体,蛋白质和编码它们的核酸来预防和治疗痘病毒感染的方法。
-
公开(公告)号:US5149660A
公开(公告)日:1992-09-22
申请号:US712683
申请日:1991-06-10
IPC分类号: A61K39/00 , C07K14/035 , G01N33/569 , G01N33/68
CPC分类号: G01N33/6854 , C07K14/005 , G01N33/56994 , A61K39/00 , C12N2710/16622
摘要: Disclosed are diagnostic reagents for use in detection of Herpes Simplex Virus Type 1 antibodies or Herpes Simplex Virus Type 2 antibodies comprising novel Herpes Simplex Virus envelope glycoproteins gD-1 and gD-2, immunologically active fragments thereof, immunologically synthetic replicas, thereof, and specific polypeptides comprising specific amino acid sequences.
摘要翻译: 公开了用于检测单纯疱疹病毒1型抗体或单纯疱疹病毒2型抗体的诊断试剂,其包含新型单纯疱疹病毒包膜糖蛋白gD-1和gD-2,其免疫学活性片段,免疫合成复制品,以及特异性 包含特定氨基酸序列的多肽。
-
公开(公告)号:US4745182A
公开(公告)日:1988-05-17
申请号:US696582
申请日:1985-01-31
IPC分类号: A61K20060101 , A61K39/245 , A61K39/395 , A61K39/42 , A61P31/12 , B43L1/04 , C07K20060101 , C07K1/16 , C07K1/22 , C07K14/00 , C07K14/005 , C07K14/03 , C07K14/035 , C07K14/195 , C07K16/00 , C07K16/08 , C07K19/00 , C12N20060101 , C12N5/00 , C12N5/10 , C12N5/12 , C12N15/00 , C12N15/02 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/569 , G01N33/571 , G01N33/577 , C07K15/00
CPC分类号: C07K16/087 , C07K14/005 , C12N2710/16622 , Y10S435/948 , Y10S530/808 , Y10S530/809 , Y10S530/81 , Y10S530/811 , Y10S930/224
摘要: Disclosed are antibody substances displaying unique, multi-specific immunoreactivities with respect to glycoprotein D of Herpes Simplex Virus types 1 and 2 (HSV gD-1 and gD-2) and structurally related compounds. Illustratively, an IgG Type 2 monoclonal antibody material produced by mouse-mouse hybridoma cell line A.T.C.C. No. HB8606 is capable of in vitro neutralization of HSV-1 and HSV-2 infectivity and of specific immunological reactivity and reversible immunobinding with natrually-occuring and recombinant gD-1 and gD-2 in both native and denatured conformations as well as with proteinaceous materials (produced, e.g., by proteolytic digestion of naturally-occurring materials, by recombinant methods, or by polymerization of amino acids) which comprise a primary structural conformation substantially duplicating part or all of that which is predicted to be extant at residues 266 through 287 of gD-1 and gD-2 [i.e., PELA(or V)PEDPEDSALLEDPV(or A)GTVA(or S)]. Disclosed also are novel procedures for detection, quantification and isolation by affinity purification of gD-1, gD-2 and structurally related compounds.
摘要翻译: 公开了针对1型和2型单纯疱疹病毒(HSV gD-1和gD-2)和结构相关化合物的糖蛋白D显示独特,多特异性免疫反应性的抗体物质。 说明性地,由小鼠 - 小鼠杂交瘤细胞系A.T.C.C.生产的IgG 2型单克隆抗体材料。 HB8606能够体外中和HSV-1和HSV-2感染性以及特异性免疫反应性和可天然存在的重组gD-1和gD-2在天然和变性构象以及蛋白质样品中的可逆免疫结合 材料(通过天然存在的材料的蛋白水解消化,通过重组方法或通过氨基酸的聚合产生),其包含主要结构构象,其基本上复制了预计在残基266至287存在的部分或全部 的gD-1和gD-2 [即,PELA(或V)PEDPEDSALLEDPV(或A)GTVA(或S)]。 还公开了通过亲和纯化gD-1,gD-2和结构相关化合物进行检测,定量和分离的新方法。
-
公开(公告)号:US4709011A
公开(公告)日:1987-11-24
申请号:US734063
申请日:1985-05-15
IPC分类号: A61K39/00 , C07K14/035 , G01N33/569 , C07K7/06 , A61K39/12 , C07K7/08
CPC分类号: G01N33/56994 , C07K14/005 , G01N33/569 , A61K39/00 , C12N2710/16622 , Y10S930/224
摘要: Disclosed are immunologically active preparations of Herpes simplex virus envelope glycoproteins, gD-1 and gD-2. Preferably purified through use of a monoclonal anti-gD antibody immunodsorbent, gD-1 and gD-2 preparations are incorporated in vaccines useful in generating immunological responses protective against Herpes simplex virus disease states. Disclosed also is the preparation and use in vaccination procedures of synthetic polypeptides comprising amino acid squences which are: (1) substantially common to both gD-1 and gD-2; (2) cumulatively hydrophilic in nature; (3) specifically immunoreactive with a type common, monoclonal anti-gD antibody of Group VII classification. Vaccines incorporating the synthetic polypeptides give rise to protective immunological responses, e.g., they protect mice against Herpes simplex.
摘要翻译: 公开了单纯疱疹病毒包膜糖蛋白gD-1和gD-2的免疫活性制剂。 优选通过使用单克隆抗gD抗体免疫吸附剂纯化,gD-1和gD-2制剂掺入可用于产生针对单纯疱疹病毒病状态的免疫应答的疫苗中。 还公开了包含氨基酸序列的合成多肽的疫苗接种程序的制备和应用,其为:(1)gD-1和gD-2基本上共同的; (2)性质上累积亲水; (3)与第VII类分类的常见的单克隆抗gD抗体特异性免疫反应。 掺入合成多肽的疫苗产生保护性免疫应答,例如它们保护小鼠免于单纯疱疹。
-
公开(公告)号:US20130171234A1
公开(公告)日:2013-07-04
申请号:US13578976
申请日:2011-02-25
IPC分类号: A61K39/245
CPC分类号: A61K39/245 , A61K39/12 , A61K2039/5252 , A61K2039/53 , A61K2039/55505 , A61K2039/55555 , A61K2039/55572 , A61K2039/70 , C07K14/005 , C12N2710/16622 , C12N2710/16634
摘要: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
摘要翻译: 本公开一般涉及1型和/或2型单纯疱疹病毒(HSV)的疫苗组合物。疫苗包含病毒的分离的抗原或糖蛋白亚基,任选地具有佐剂,例如阳离子脂质体DNA复合物(CLDC)。 本公开还公开了使用这些组合物接种受试者的方法。
-
-
-
-
-
-
-
-
-